Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Outlook Therapeutics, Inc.
Last earnings +0.4% on 2026-05-18
High return on equity (193.9%); but unprofitable (net margin -4416.2%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Outlook Therapeutics, Inc. shows $1.41M in FY2025 revenue, a -4416.2% net margin, and 193.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001649989, latest 10-Q filed 2026-05-15) · EODHD · rules-based read · as of 6/17/2026, 7:45:27 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.41M |
| Gross profit | — | — | — | — | $57.2K |
| Operating income | -$51.7M | -$63.1M | -$53.1M | -$71.7M | -$67.1M |
| Net income | -$53.2M | -$66.1M | -$59.0M | -$75.4M | -$62.4M |
| Diluted EPS | -$0.35 | -$0.31 | -$4.72 | -$4.06 | -$1.79 |
| Net margin | — | — | — | — | -4416.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Crowd attention, not a quality signal — weigh it against the figures above. All trending →
501 tracked peers · median
Last 90 days: 6 open-market buys · 0 sales
| 2026-06-02 | Haddadin Yezan Munther Director | Buy | 29.0K @ $0.83 | $24.1K |
| 2026-05-28 | Sukhtian Ghiath M. Director | Buy | 8.54M @ $0.59 | $5.00M |
| 2026-05-27 | Sukhtian Faisal Ghiath Director | Buy | 122K @ $0.41 | $50.0K |
| 2026-05-26 | Haddadin Yezan Munther Director | Buy | 34.0K @ $0.44 | $15.0K |
| 2026-05-26 | THURMAN RANDY H Director | Buy | 5.00K @ $0.43 | $2.15K |
| 2026-05-26 | HILZINGER KURT J Director | Buy | 400K @ $0.44 | $177K |